Skip to main content

Richard E. Pratley, MD

Richard E. Pratley, MD

Medical Director at the AdventHealth Diabetes Institute, Senior Investigator, Diabetes Program Lead at the Translational Research Institute

Translational Research, Infectious Disease

Pratley

Overview

Richard Pratley, MD, is a board-certified internal medicine physician and nationally recognized diabetes expert with advanced training in gerontology, geriatrics and clinical physiology and metabolism. He sees patients at AdventHealth Medical Group’s diabetes and endocrine specialty practice in Orlando and The Villages while also serving as the Medical Director of the AdventHealth Diabetes Institute and as a senior scientist in diabetes research for AdventHealth. He is a leading authority on new and emerging treatments for diabetes and its comorbidities, which is why many area physicians refer their patients to him for advanced diabetes care. Dr. Pratley earned his medical degree at Wayne State University in Detroit and undertook his residency at the University of Michigan. He next completed three consecutive fellowships in clinical physiology and metabolism, gerontology and geriatrics, and geriatrics at the National Institute on Aging in Baltimore, Johns Hopkins University and the University of Michigan, respectively.

Articles

Efficacy and safety of efpeglenatide in key patient subgroups from the BALANCE randomized trial, stratified by pre-diabetes status, BMI, and age at baseline

BMJ OPEN DIABETES RESEARCH & CARE

2022

Y Effects of Vitamin D Supplementation on Insulin Sensitivity and Secretion in Prediabetes

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

2022

Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial.

Circulation

2022

Indirect treatment comparisons: Choosing the right tool for the job.

Diabetes, obesity & metabolism

2022

ICU outcomes and survival in patients with severe COVID-19 in the largest health care system in central Florida

PLOS ONE

2021

Investigation of Extracellular Vesicles From SARS-CoV-2 Infected Specimens: A Safety Perspective

FRONTIERS IN IMMUNOLOGY

2021

Prototype of an evidence-based tool to aid individualized treatment for type 2 diabetes

DIABETES OBESITY & METABOLISM

2021

Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial

DIABETES CARE

2021

Impact of bariatric surgery and weight loss medications in adults with type 1 diabetes in the T1D Exchange Clinic Registry

JOURNAL OF DIABETES AND ITS COMPLICATIONS

2021

Kidney outcomes using a sustained >= 40% decline in eGFR: A meta-analysis of SGLT2 inhibitor trials

CLINICAL CARDIOLOGY

2021

Education & Training

Education

Wayne State University School of Medicine; University of Michigan- Ann Arbor; John Hopkins School of Medicine; University of Michigan - Dearborn

Residency

University of Michigan, Ann Arbor, MI

Fellowship

University of Michigan, Ann Arbor, MI; Johns Hopkins University, Baltimore, MD

Board Certifications

American Board of Internal Medicine

Associated Clinical Trials

NCT01942694

D2D: Vitamin D and Type 2 Diabetes

Icon for trial | D2D: Vitamin D and Type 2 Diabetes

Diabetes is a serious condition affecting about 1 in 10 people in the United States. Lifestyle changes, such as healthy eating, exercise and weight loss, can decrease the chances of developing diabetes. However, many people st ...

NCT01843127

GILEAD: A Phase 1, Randomized, Single-blind, Placebo-controlled, Multiple-dose, Two-sequence, Cross-over Study to Evaluate the Effect of Ranolazine on Glucagon Secretion in Subjects with Type 2 Diabetes Mellitus, Followed by An Open-label, Single-dose, Exenatide Active-control Period

Icon for trial | GILEAD: A Phase 1, Randomized, Single-blind, Placebo-controlled, Multiple-dose, Two-sequence, Cross-over Study to Evaluate the Effect of Ranolazine on Glucagon Secretion in Subjects with Type 2 Diabetes Mellitus, Followed by An Open-label, Single-dose, Ex

The primary purpose of this study is to understand the reasons why Ranolazine may potentially treat patients with T2DM. Ranolazine has been shown to block glucagon and therefore results in a lowering of blood glucose levels. Th ...

NCT01664624

ROF: A Phase 1b, Randomized, Double-Blind, Active Comparator (Open-Label Exenatide) Controlled Study to Evaluate the Effect of Roflumilast Plus Alogliptin on Postprandial Active GLP-1 Level and 24-hour Glucose Level in Subjects with Type 2 Diabetes Who Are Inadequately Controlled on a Stable Dose of Metformin

Icon for trial | ROF: A Phase 1b, Randomized, Double-Blind, Active Comparator (Open-Label Exenatide) Controlled Study to Evaluate the Effect of Roflumilast Plus Alogliptin on Postprandial Active GLP-1 Level and 24-hour Glucose Level in Subjects with Type 2 Diabetes Who Ar

You are being asked to participate in this study because you have type 2 diabetes and are being treated with metformin. Despite the availability of several different classes of medications to treat the diabetes, many patients a ...

NCT04432090

PHROG: A randomized, placebo-controlled, double-blinded cross-over study of the pharmacologic action of a GPR119 agonist on glucagon counter-regulation during insulin-induced hypoglycemia in Type 1 diabetes mellitus.

Icon for trial | PHROG: A randomized, placebo-controlled, double-blinded cross-over study of the pharmacologic action of a GPR119 agonist on glucagon counter-regulation during insulin-induced hypoglycemia in Type 1 diabetes mellitus.

This study is currently enrolling.

People with type 1 diabetes are at high risk of developing hypoglycemia because of insulin treatment and because their body is less effective at increasing the levels of sugar in their blood when it is low. In this research stu ...

RECODE: Researching Covid Outcomes in Diabetes

Icon for trial | RECODE: Researching Covid Outcomes in Diabetes

This study is currently enrolling.

We invite you to take part in a research study because you have previously had a confirmed diagnosis for COVID-19 (the new coronavirus) disease. You have recovered, or are recovering from this disease, with no fever or cough wi ...

NCT04628481

DOMPE: A phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of 400 mg twice a day oral ladarixin in patients with new-onset type 1 diabetes and a low residual β-cell function at baseline.

Icon for trial | LDX0319 DOMPE: A phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of 400 mg twice a day oral ladarixin in patients with new-onset type 1 diabetes and a low residual β-cell function at baseline

This study is currently enrolling.

The purpose of this study is to check and collect data of how the body absorbs, distributes and gets rid of the study drug in the blood during the first cycle of LDX0319 study treatment. These data will help improve knowledge a ...

NCT04016662

AIDE: A Randomized Cross-over Trial Evaluating Automated Insulin Delivery Technologies on Hypoglycemia and Quality of Life in Elderly Adults with Type 1 Diabetes (Automated Insulin Delivery in Elderly with Type 1 Diabetes [AIDE t1D])

Icon for trial | AIDE AIDE: A Randomized Cross-over Trial Evaluating Automated Insulin Delivery Technologies on Hypoglycemia and Quality of Life in Elderly Adults with Type 1 Diabetes (Automated Insulin Delivery in Elderly with Type 1 Diabetes [AIDE t1D])

This study is currently enrolling.

The purpose of this study is to see if features of an automated insulin delivery system (study system) can reduce low blood sugar (hypoglycemia) in older adults with type 1 diabetes. We expect up to 150 people will take part in ...